175 related articles for article (PubMed ID: 27823655)
1. The immune landscape of myelodysplastic syndromes.
Fozza C; Crobu V; Isoni MA; Dore F
Crit Rev Oncol Hematol; 2016 Nov; 107():90-99. PubMed ID: 27823655
[TBL] [Abstract][Full Text] [Related]
2. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?
Fozza C; Longinotti M
Eur J Haematol; 2012 May; 88(5):380-7. PubMed ID: 22296182
[TBL] [Abstract][Full Text] [Related]
3. Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant.
Fozza C
Crit Rev Oncol Hematol; 2019 Jan; 133():112-119. PubMed ID: 30661647
[TBL] [Abstract][Full Text] [Related]
4. [Clonal expanded T-cell repertoire in MDS].
Li YQ; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):793-7. PubMed ID: 20561453
[TBL] [Abstract][Full Text] [Related]
5. [The research update on cellular immune abnormality in myelodysplastic syndrome--review].
Xu F; Liu T
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):673-7. PubMed ID: 14706159
[TBL] [Abstract][Full Text] [Related]
6. The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS.
Fozza C; La Nasa G; Caocci G
Crit Rev Oncol Hematol; 2019 Oct; 142():51-57. PubMed ID: 31376677
[TBL] [Abstract][Full Text] [Related]
7. The role of the immune system in myelodysplasia: implications for therapy.
Sloand EM; Rezvani K
Semin Hematol; 2008 Jan; 45(1):39-48. PubMed ID: 18179968
[TBL] [Abstract][Full Text] [Related]
8. Immune alterations in untreated and treated myelodysplastic syndrome.
Mewawalla P; Dasanu CA
Expert Opin Drug Saf; 2011 May; 10(3):351-61. PubMed ID: 21417834
[TBL] [Abstract][Full Text] [Related]
9. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes.
Zhao ZG; Xu W; Yu HP; Fang BL; Wu SH; Li F; Li WM; Li QB; Chen ZC; Zou P
Cancer Lett; 2012 Apr; 317(2):136-43. PubMed ID: 22240014
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM
Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293
[TBL] [Abstract][Full Text] [Related]
11. Targeting immune dysregulation in myelodysplastic syndromes.
Olnes MJ; Sloand EM
JAMA; 2011 Feb; 305(8):814-9. PubMed ID: 21343581
[TBL] [Abstract][Full Text] [Related]
12. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
[TBL] [Abstract][Full Text] [Related]
13. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
Stankov K; Stankov S; Katanic J
Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
Warlick ED; Miller JS
Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
[TBL] [Abstract][Full Text] [Related]
15. Immune Mechanisms in Myelodysplastic Syndrome.
Glenthøj A; Ørskov AD; Hansen JW; Hadrup SR; O'Connell C; Grønbæk K
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27314337
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.
Sloand EM; Barrett AJ
Hematol Oncol Clin North Am; 2010 Apr; 24(2):331-41. PubMed ID: 20359629
[TBL] [Abstract][Full Text] [Related]
17. The role of T-cells in the pathogenesis of myelodysplastic syndromes: passengers and drivers.
Fozza C; Longinotti M
Leuk Res; 2013 Feb; 37(2):201-3. PubMed ID: 23218025
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes.
Deshet-Unger N; Oster HS; Prutchi-Sagiv S; Maaravi N; Golishevski N; Neumann D; Mittelman M
Leuk Res; 2017 Jan; 52():20-27. PubMed ID: 27870945
[TBL] [Abstract][Full Text] [Related]
19. The burden of autoimmunity in myelodysplastic syndromes.
Fozza C
Hematol Oncol; 2018 Feb; 36(1):15-23. PubMed ID: 28449370
[TBL] [Abstract][Full Text] [Related]
20. Immunologic abnormalities in myelodysplastic syndromes.
Hamblin T
Hematol Oncol Clin North Am; 1992 Jun; 6(3):571-86. PubMed ID: 1613007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
